Preliminary clinical trial and the physiologic disposition of 4(5)-(3,3-dimethyl-1-triazeno)imidazole-5(4)-carboxamide in man.
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000032:analysis / Q000097:blood / Q000627:therapeutic use* / Q000652:urine; D001943:Breast Neoplasms / Q000188:drug therapy; D003110:Colonic Neoplasms / Q000188:drug therapy; D004304:Dosage Forms; D005919:Glomerular Filtration Rate; D006801:Humans; D007093:Imidazoles / Q000097:blood / Q000627:therapeutic use* / Q000652:urine; D007275:Injections, Intravenous; D008175:Lung Neoplasms / Q000188:drug therapy; D008545:Melanoma / Q000188:drug therapy*; D009369:Neoplasms / Q000188:drug therapy*; D012468:Salivary Gland Neoplasms / Q000188:drug therapy; D012509:Sarcoma / Q000188:drug therapy; D013997:Time Factors
D000970:Antineoplastic Agents; D004304:Dosage Forms; D007093:Imidazoles